(Q40275250)

19 September 2017

title

A combination of E. coli DNA fragments and modified lipopolysaccharides as a cancer immunotherapy (English)

1 reference

19 September 2017

0 references

1 reference

1 reference

Yang Je Cho

1

1 reference

19 September 2017

Bo Young Ahn

2

1 reference

19 September 2017

Na Gyong Lee

3

1 reference

19 September 2017

Dong Hyeon Lee

4

1 reference

19 September 2017

Doo-Sik Kim

5

1 reference

19 September 2017

language of work or name

English

0 references

publication date

6 May 2006

1 reference

19 September 2017

1 reference

19 September 2017

volume

24

1 reference

19 September 2017

issue

31-32

1 reference

19 September 2017

page(s)

5862-5871

1 reference

Coley's toxins in perspective.

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Biological activities and antitumor effects of synthetic lipid a analog linked n-acylated serine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Endotoxin, toll-like receptor 4, and the afferent limb of innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Role of tumour necrosis factor in the tumour-necrotizing activity of agents with diverging toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

inferred from DOI database lookup

7 January 2021

based on heuristic

Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

A Toll-like receptor recognizes bacterial DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

CpG motifs in bacterial DNA and their immune effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Immunostimulatory DNA sequences and cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

CpG motifs in bacterial DNA trigger direct B-cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

CpG oligodeoxynucleotide enhances tumor response to radiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Effect of different chemically modified oligodeoxynucleotides on immune stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Differences in macrophage activation by bacterial DNA and CpG-containing oligonucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Whole blood cultures to assess the immunostimulatory activities of CpG oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Quantification of bacterial lipopolysaccharides by the purpald assay: measuring formaldehyde generated from 2-keto-3-deoxyoctonate and heptose at the inner core by periodate oxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Improved method for the removal of endotoxin from DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Recombinant immunotoxins for treating cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

An endotoxin-induced serum factor that causes necrosis of tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Tumour necrosis factor alpha: a potential target for the therapy of solid tumours.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Stimulation of cultured colon 26 cells with TNF-alpha promotes lung metastasis through the extracellular signal-regulated kinase pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

CpG motifs: the active ingredient in bacterial extracts?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Bacterial DNA causes septic shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-alpha through a post-transcriptional mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-alpha production through activation of NF-kappaB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.048

10.1016/J.VACCINE.2006.04.048

7 January 2021

Identifiers

DOI

1 reference

19 September 2017

1 reference